Hikma v. Amarin Oral Argument Watch Party

Do you love watching history unfold in real time?

Are you passionate about patent law, pharmaceutical litigation, or just want to witness some top-tier legal sparring? Then please join us for a live watch party of the oral arguments in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. before the United States Supreme Court! This case is a big deal — and not just for pharma lawyers. The Supreme Court is taking on two questions that could reshape how induced patent infringement claims are pleaded in the generic drug space:

1. The "Generic Version" Question: When a generic drugmaker fully carves out a patented use from its label, can it still be liable for induced infringement just because it calls its product a "generic version" of the branded drug and references publicly available information — like sales figures — about that drug?
2. The "No Mention, No Claim?" Question: Can a complaint survive if it doesn't allege that the defendant ever instructed, encouraged, or even mentioned the patented use? What does it really take to plead induced infringement of a patented method?

Whether you're a patent litigator, an IP enthusiast, a pharma industry insider, or just someone who gets excited when the justices start asking hard questions, this case has something for everyone.